Liz Girardi Müller graduated in Pharmacy from the Federal University of Santa Maria (UFSM, Brazil) in 2009 and obtained her MSc (2011) and Ph.D. (2014) in Pharmaceutical Sciences from the Federal University of Rio Grande do Sul (UFRGS). Her doctoral research focused on the antidepressant-like mechanisms of a Valeriana glechomifolia extract obtained via supercritical CO₂, integrating behavioral, neurochemical, and mechanistic approaches. During this period, she completed a one-year research internship at INMED/INSERM-Aix-Marseille University (France), funded by CAPES, and conducted complementary research at the University of São Paulo (USP, Brazil), strengthening her expertise in neuropsychopharmacology. She then pursued a postdoctoral fellowship at UFRGS (2015–2016), focusing on CNS-active compounds and neuronal plasticity. She later joined the University of Chapecó (Brazil), where she founded and led the Preclinical Neuropsychopharmacology Research Group, supervised graduate and undergraduate students, taught pharmacology, and coordinated a graduate program (2021–2024). In 2024, she was a visiting researcher at Aarhus University (Denmark), working on neuroinflammation and neuroplasticity. Currently, she is a Scientist at iBET (Portugal), focusing on natural products, neuroactive compounds, and translational cellular models.
Liz Girardi Müller graduated in Pharmacy from the Federal University of Santa Maria (UFSM, Brazil) in 2009 and obtained her MSc (2011) and Ph.D. (2014) in Pharmaceutical Sciences from the Federal University of Rio Grande do Sul (UFRGS). Her doctoral research focused on the antidepressant-like mechanisms of a Valeriana glechomifolia extract obtained via supercritical CO₂, integrating behavioral, neurochemical, and mechanistic approaches. During this period, she completed a one-year research internship at INMED/INSERM-Aix-Marseille University (France), funded by CAPES, and conducted complementary research at the University of São Paulo (USP, Brazil), strengthening her expertise in neuropsychopharmacology. She then pursued a postdoctoral fellowship at UFRGS (2015–2016), focusing on CNS-active compounds and neuronal plasticity. She later joined the University of Chapecó (Brazil), where she founded and led the Preclinical Neuropsychopharmacology Research Group, supervised graduate and undergraduate students, taught pharmacology, and coordinated a graduate program (2021–2024). In 2024, she was a visiting researcher at Aarhus University (Denmark), working on neuroinflammation and neuroplasticity. Currently, she is a Scientist at iBET (Portugal), focusing on natural products, neuroactive compounds, and translational cellular models.